| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7da5c8e8c3e8261efe7e698c7198681b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6893 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-44 |
| filingDate |
2018-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae81fa91ebcd0636d4e2b7f9dbea9e71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f53b6ea49d995768fbbea30b77dbd88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26c17fa71f749fa4ba18545b50501b4e |
| publicationDate |
2018-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018312555-A1 |
| titleOfInvention |
Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the pfr1 protein of leishmania infantum with specific immunodominant epitopes |
| abstract |
The present invention claims an isolated nucleotide sequence characterized by encoding the PFR1 protein of Leishmania infantum or a fragment thereof. This PFR1 protein or a fragment thereof comprises at least a selected immunodominant epitope between the following group: SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7 and SEQ ID No: 8, where the immunodominant epitope is able to induce an antigen-specific T cell cytotoxic immune response in an animal, against the kinetoplastids causing the leishmaniasis disease. The immunodominant epitopes are cytotoxic T-lymphocyte activators and they present a high binding affinity for A2 type MHC Class I molecule. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10919946-B2 |
| priorityDate |
2011-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |